source
- NeuShen Therapeutics raises over $80 million to advance three brain-health drug candidatesNeuShen Therapeutics, a biotech with operations in Shanghai and Boston, announced it has closed a Series B financing round of more than $80 million. The capital will be used to move three clinical…
- Menarini secures European rights to Chinese GLP-1 obesity drugMenarini Group, a large family‑owned pharmaceutical company in Italy, has obtained the European commercial rights to a GLP‑1 agonist developed by China’s Gan & Lee. The agreement gives Menarini a…